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Recent evidence indicates that basal cerebral conduit vessels dilate with hypercapnia, with a
nitric oxide (NO) mechanism explaining one way in which parenchymal cerebral arterioles dilate.
However, whether NO affects basal cerebral artery dilatation remains unknown. This study
quantified the effect of an exogenous NO donor [sodium nitroglycerin (NTG); 0.4 mg sublingual
spray] on the right middle cerebral artery (rMCA) cross-sectional area (CSA), blood velocity and
overall blood flow. Measures of vessel CSA (7 T magnetic resonance imaging) and MCA blood
velocity (transcranial Doppler ultrasound) were made at baseline (BL) and after exogenous NTG
or placebo (PLO) administration in young, healthy individuals (n = 10, two males, age range
20–23 years). The CSA increased in the rMCA [BL, 5.2 ± 1.2 mm2; PLO, 5.4 ± 1.5 mm2; NTG,
6.6 ± 1.5 mm2, P < 0.05; mean ± SD]. Concurrently, rMCA blood velocity decreased from BL
during NTG compared with PLO (BL, 67 ± 10 cm s−1; PLO, 62 ± 10 cm s−1; NTG, 59 ± 9.3 cm s−1,
P < 0.05; mean ± SD]. However, total MCA blood flow did not change with NTG or PLO [BL,
221±37.4mlmin−1; PLO, 218±35.0mlmin−1; NTG, 213±46.4mlmin−1). Therefore, exogenous
NOmediates a dilatory response in the rMCA, but not in its downstream vascular bed.
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1 INTRODUCTION
Optimal cerebral blood flow (CBF) is achieved through changes
in perfusion pressure (Nagata et al., 2016) and adjustments in
cerebrovascular conductance (Aaslid, 1992). The control of cerebral
microvasculature has received considerable attention (Hamel, 2005),
whereas the role of the large conduit cerebral arteries in CBF
control and its distribution in conscious humans has only recently
gained research focus. Early data obtained in larger animal studies
(Mchedlishvili, Mitagvaria, & Ormotsadze, 1973; Yoshida, Meyer,
Sakamoto, & Handa, 1966) and literature reviews (Faraci & Heistad,
1990) suggest that large intracranial arteries associatedwith the circle
ofWillis arekey contributors to total cerebral vascular resistance.Also,
evidence using high-field magnetic resonance imaging (MRI) indicate
that these vessels constrict with hypocapnia and dilate with hyper-
capnia (Coverdale, Lalande, Perrotta, & Shoemaker, 2015; Kellawan
et al., 2016; Verbree et al., 2014). Therefore, large vessels contribute
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to CBF control. Of particular interest are the middle cerebral arteries
(MCAs), which are the largest of the cranial vessels and distribute
80% of the blood flow to the brain (Nagata et al., 2016). Therefore,
these vessels are the most studied with respect to cerebrovascular
reactivity.
In young and healthy states, hypercapnia elicits an increase in
CBF through complex mechanisms that include endothelial (Faraci
& Heistad, 1998; Furchgott & Vanhoutte, 1989) and extravascular
changes in pH (Kontos, Raper, & Patterson, 1977) and neuronal
contributions to the vascular contractile state (Ainslie & Duffin, 2009;
Toda, 1983). Of these mechanisms, nitric oxide (NO) represents a key
endothelial factor stimulated by carbon dioxide (Hamel, 2004; Lavi,
Egbarya, Lavi, & Jacob, 2003) affecting vascular tone. Although these
effects are known for parenchymal vascular beds, the direct effect
of NO on the basal cerebral arteries, and their upstream subcranial
arteries (i.e. vertebral arteries and internal carotid arteries), remains
unknown, particularly in humans.
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NewFindings
• What is the central question of this study?
Nitric oxide causes dilatation in peripheral vessels;
however, whether nitric oxide affects basal cerebral
artery dilatation has not been explored.
• What is themain finding and its importance?
This study demonstrated that vasodilatation occurs
in the right middle cerebral artery in response to
exogenous nitric oxide.However, blood velocity decreased
and, therefore, overall cerebral blood flow remained
unchanged. This study provides new insight into the role
of nitric oxide in cerebral blood flow control.
Drugs such as sodium nitroglycerin (NTG) deliver an exogenous
source of NO to large coronary and peripheral conduit vessels, where
they cause dilatation (Arnold, Mittal, Katsuki, &Murad, 1977; Ignarro,
Ross, & Tillisch, 1991; Parratt, 1979).When administered sublingually,
this lipid-soluble drug is rapidly absorbedover themucosalmembranes
in the mouth (Zhang, Zhang, & Streisand, 2002). Sodium nitroglycerin
has a half-life of ∼2.5 min (Kirsten, Nelson, Kirsten, & Heintz,
1998b) and acts as a metabolism-dependent NO donor, amplifying
NOproduction and eliciting subsequent vasodilatory effect(s) (Kirsten
et al., 1998b; Kirsten, Nelson, Kirsten, & Heintz, 1998a). Therefore,
NTG is viewed as an ideal drug both for clinical use and for studying
non-endothelial vasomotor function (Mao et al., 2012). In addition,
NTG can cross the blood–brain barrier and act directly on the vascular
smooth muscle cells (independent of the endothelium), where it is
assumed to biotransform toNO (Chen, Zhang, & Stamler, 2002). Based
on observations in the brachial artery vascular bed, exogenous NO
dilates conduit arteries some distance from the heart, but with little
change in total blood flow and systemic blood pressure, owing to
concurrent vasoconstriction (preventing dilatation) in thedownstream
vascular bed (Anderson, Meredith, Ganz, Selwyn, & Yeung, 1994;
Ignarro et al., 1991). Consequently, NTG may provide a useful tool
to study NO-mediated control of large cerebral arteries. Despite its
popular use in patients with cardiovascular disease, the role of NTG
(and, therefore, NO) in the cerebrovasculature remains unstudied.
Therefore, this study tested the hypothesis that NO causes vaso-
dilatation in the MCA of the circle of Willis. Additional focus on its
blood flow provided insight into both the conduit vessel and the down-
stream vascular bed in response to exogenous NO.
2 METHODS
2.1 Ethical approval
Each participant was required to provide informed written consent
to the protocols, which were approved by the Western University
Health Sciences Research Ethics Board (HSREB: 107620). This study
conformed to the standards set by theDeclaration of Helsinki except for
registration in a database.
2.2 Participants
Ten young, healthy individuals participated in this study (eight
females, unknownmenstrual phase; Table1). Participants expressedno
history of medication, cardiovascular disease or neurological disorder.
Participants refrained from alcohol, caffeine and exercise for 12 h
before testing.
2.3 Experimental protocol
Data were collected during two testing sessions that were performed
on separate days: (i) a laboratory session; and (ii) aMRI session. In each
session, measurements were made before and after NTG treatment
(0.4 mg, Nitrolingual Pumpspray; Sanofi, Laval, QC, Canada) and
separately during a placebo (PLO), composed of water and peppermint
oil to match the flavour of NTG. Each treatment was provided via
sublingual spray. All participants were blinded to treatment, and
treatments were administered in a random order in the laboratory
session that was then repeated in theMRI session.
2.3.1 Laboratory sessionmeasurements
Height, weight and age were acquired from each participant (Table 1).
Supine measurements included brachial artery diameter and blood
velocity [duplex ultrasoundmachine with a 10MHz probe (Vivid 7; GE
Healthcare, Chicago, IL, USA)] and right MCA (rMCA) blood velocity
[2MHz transcranial Doppler (TCD) transducer; Neurovision, Multigon
Industries, Elmsford, NY, USA]. The brachial artery data provided
information about the systemic effects of NTG and PLO. Additional
measurements included finger arterial blood pressure (Finometer;
Finapres Medical Systems, Enschede, The Netherlands) corrected to
brachial sphygmomanometric values, Finometer-derived measures of
stroke volume (SV) and cardiac output (CO), based on the Modelflow
algorithm, heart rate (HR; three-lead ECG) and partial pressure of end-
tidal carbon dioxide (PET,CO2 ; AD Instruments; Colorado Springs, CO,
USA). All values were recorded at 1000 Hz using LabChart software
(AD Instruments, Colorado Springs, CO, USA).
Following establishment of stable variables, 5 min of supine
rest allowed for baseline (BL) measurements. During this time, two
brachial artery images were captured at the beginning and end of
the 5 min period. During NTG or PLO administration, collection of
measurements occurred for 20 min each, and brachial artery images
were captured every minute for the first 8 min to capture the peak
effect of the drug, then at the 10th, 15th and 20th minute post-
treatment to follow recovery.
TABLE 1 Participant characteristics
Males/females (n) 10, 2/8
Age (years) 22 ± 1
Height (cm) 171 ± 7
Bodymass index (kgm−2) 21 ± 2
Systolic blood pressure (mmHg) 117 ± 13
Diastolic blood pressure (mmHg) 66 ± 7
Values aremeans± SD.
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2.3.2 MRI sessionmeasurements
All cerebrovascular anatomy measurements were performed on a
7 T neuro-optimized MRI scanner (Siemens MAGNETOM; Erlangen,
Germany) using an in-house-built eight-channel transmit, 32-channel
head coil. Cross-sectional area (CSA) measurements were made of the
rMCA using a T1-weighted 3D SPACE pulse sequence (Park, Mugler,
Horger, & Kiefer, 2007) using a sagittal orientation, at high resolution
(0.5mm isotropic,whole brain),with the following imaging parameters:
TE = 8.2 ms, TR = 700 ms, FOV = 224 mm, matrix = 448 × 448 × 256,
turbo factor = 96, BW = 587 Hz/px, iPat = 2 and TA = 5:38 min. A
radial trajectory minimized the echo time, as it is robust to motion and
the distribution of artefacts (Glover & Pauly, 1992). First, a baseline
T1 image (requiring 5–6 min to complete) was captured. Thereafter,
a second and third T1 image were captured, commencing at 2 min
after NTG or PLO administration to capture the period of peak
dilatation. Of note, our laboratory demonstrated that MCA dilatation
in response to hypercapnia develops progressively, with the peak
response occurring at 3–4 min (Coverdale et al., 2015). Additionally,
peak brachial dilatation in response to NTG occurs ∼3 min post-
spray (Ducharme, Dupuis, McNicoll, Harel, & Tardif, 1999). Therefore,
we anticipate that our imaging parameters capture a time period of
maximal NTG effect.
Thereafter, a time-of-flight (TOF) image was captured for
structural/topological layout of the brain's conduit artery angiogram
(Figure 1). As in the laboratory session, 20 min of recovery provided
after each treatment allowed values to return to baseline. The PET,CO2
levels were monitored continuously via a modified oxygen mask
(Trudell Medical Marketing Ltd, London, ON, Canada) with a built-in
sampling port, and a sampling line connected to a gas analyser (Biopac
MP150; Biopac Systems Inc., Montreal, QC, Canada). All MRI images
were saved as DICOM files for offline analysis.
2.4 Data analyses
Laboratory measurements of CO, SV, HR, mean arterial pressure
(MAP), PET,CO2 , MCA velocity and brachial artery velocity, averaged
over 30 s periods at every 1 min interval between 2 and 7 min
post-treatment, aligned with the T1 image acquisitions. Brachial
artery CSA calculated from brachial artery diameter measurements
(EchoPAC software; GE 7 Vingmed Ultrasound, Chicago, IL, USA)
were taken every minute between 2 and 7 min post-treatment. OsiriX
software (Pixmeo SARL, Bernex, Switzerland) enabled measurements
of the rMCA CSA in all three conditions, using previously described
methods (Al-Khazraji, Shoemaker, Gati, Szekeres, & Shoemaker, 2018).
Anatomical location fiduciaries in the 3D images were obtained
from the baseline images for each participant and condition. These
anatomical locators, depth and contrast values enabled the location
and measurement of vessel CSA at the same vascular site during the
PLO andNTG treatments (Figure 2). In addition, two trained observers
(J.M.S. and B.K.A.), blinded to treatment and participant information,
measured CSA independently.
F IGURE 1 Time-of-flight magnetic resonance images of the circle of Willis at 7 T from a cranial (a) and a dorsal (b) view. Abbreviations: l/rACA,
left/right anterior cerebral artery; l/rICA, left/right internal carotid artery; l/rMCA, left/rightmiddle cerebral artery; and l/rPCA, left/right posterior
cerebral artery
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F IGURE 2 Right middle cerebral artery cross-sectional area before (a) and after (b) measurement and comparison of a blinded baseline (c) and
unknown treatment (d) of T1 images in Osirix
TABLE 2 Haemodynamic parameters for baseline (BL), placebo
(PLO) and nitroglycerin (NTG) conditions
Parameter BL PLO NTG
Cardiac output (l min−1) 4.9 ± 1.9 4.8 ± 2.0 5.2 ± 1.7
Stroke volume (ml) 79 ± 32 76 ± 32 79 ± 28
Laboratory PET,CO2 (mmHg) 42 ± 4 42 ± 4 41 ± 5
MRI PET,CO2 (mmHg) 45 ± 6 45 ± 7 45 ± 7
Heart rate (beats min−1) 62 ± 10 64 ± 11 66 ± 10*
MAP (mmHg) 83 ± 12 86 ± 14 86 ± 13
rMCA V (cm s−1) 67 ± 10 62 ± 10‡ 59 ± 9.3*
rMCACSA (mm2) 5.2 ± 1.2 5.4 ± 1.5 6.6 ± 1.5*†
rMCA F (ml min−1) 221 ± 37.4 218 ± 35.0 213 ± 46.4
rMCA C (ml minmmHg−1) 2.7 ± 0.5 2.6 ± 0.8 2.6 ± 0.6
Brachial V (cm s−1) 3.0 ± 1.6 2.6 ± 1.9 2.8 ± 2.2
Brachial CSA (mm2) 7.5 ± 2.2 7.8 ± 2.3 9.0 ± 2.2*†
Brachial F (ml min−1) 14 ± 11 13 ± 12 16 ± 16
Brachial C (ml minmmHg−1) 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.2
Values are means ± SD. Abbreviations: C, conductance; CSA, cross-
sectional area;F, flow;MAP,meanarterial pressure;PET,CO2 , partial pressure
of end-tidal carbon dioxide; rMCA, right middle cerebral artery; and V,
velocity. *NTG different from BL (P < 0.05). †NTG different from PLO
(P< 0.05). ‡PLO different fromBL (P< 0.05).
During the MRI, PET,CO2 was monitored to ensure stability, and
averaged over 30 s obtained 2.5 min into the T1 scan (Table 2). The
product of blood velocity (V) andCSAquantified blood flow in theMCA
and brachial artery (flow = V × CSA). Conductance (C) for both the
brachial artery and theMCAwas also calculated as thequotient of flow
andMAP (C= flow/MAP).
2.5 Statistical analysis
The effect of treatment on the rMCA CSA and haemodynamic
outcomes was assessed using a one-way repeated-measures ANOVA,
with a Bonferroni correction for multiple comparisons. The effects of
treatment and time (each minute value) on MCA and brachial artery
blood velocity data, normalized to baseline values,were assessed using
a two-way repeated-measures ANOVA with a Bonferroni correction.
A Bland–Altman test compared the blinded analyses of rMCA CSA
from the twoobservers. Theprobability level for statistical significance
was 0.05. Statistical analyses were performed in SPSS (SPSS 23; IBM




All data passed a Sharipo–Wilk test of normality. Brachial artery CSA
increased [F(2,18) = 13.92, P < 0.001] with NTG compared with
both BL (9.0 ± 2.2 versus 7.5 ± 2.2 mm2, respectively, P < 0.01) and
PLO (7.7 ± 2.3 mm2, P < 0.05), whereas measurements for BL and
PLO treatments were similar (Figure 3a). The rMCA behaved in a
similar manner [F(2,18) = 14.13, P < 0.001], in that CSA increased








































F IGURE 3 Changes in cross-sectional area (CSA) in the brachial
artery (a) and right middle cerebral artery (rMCA; b) during baseline
(BL), placebo (PLO) and sodium nitroglycerin (NTG) treatments. *NTG
different fromBL (P< 0.05). †NTG different from PLO (P< 0.05)
during NTG administration (6.6 ± 1.5 mm2) compared with both BL
(5.2 ± 1.2 mm2, P < 0.001) and PLO (5.4 ± 1.5 mm2, P < 0.05);
however, BL and PLO values were similar (Figure 3b). The Bland–
Altman analysis of rMCA CSA between observers showed an inter-
rater bias of 0.6604± 1.075mm2 (95% confidence interval 1.45–2.77)
but no proportional bias. Post hoc power analysis (G*Power; Heinrich-
Heine-Universität, Düsseldorf, Germany) for rMCA measurements
was 0.99.
3.2 Blood velocity
Brachial artery velocity values did not change over time in either
the NTG or PLO conditions (Figure 4a). However, a significant
treatment × time interaction [F(2,18) = 87.21, P < 0.0001) indicated
that MCA blood velocity during NTG was lower than during PLO at
each time point after the first minute (Figure 4b; P< 0.05).
3.3 Other haemodynamicmeasurements
No effect of treatment was observed for MAP or PET,CO2 (Table 2).
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F IGURE 4 Velocity changes over 7min of NTG and PLO treatments,
normalized to baseline values for brachial artery (a) and right middle
cerebral artery (rMCA; b). †NTG different from PLO (P< 0.05)
with BL (66 ± 10 versus 62 ± 10 beats min−1, respectively, P < 0.05).
Calculated total flow and vascular conductance in both brachial and
rMCA vessels were similar to BL during NTG and PLO administration
(Table 2).
4 DISCUSSION
The major findings of this study are as follows: (i) the rMCA dilated
in response to NTG administration; and (ii) despite an increase in
CSA, there were no changes in overall flow, in both the MCA and
brachial artery vascular beds. Therefore, exogenous NO dilates the
large conduit basal cerebral arteries, but not the downstream vascular
beds, in both brachial and rMCA vascular beds.
Sodiumnitroglycerin is a commondrugused to treat anginapectoris
through its effect on dilatation of both large arteries and veins (Parratt,
1979). This, in turn, reduces both cardiac afterload and preload,
respectively (Ludbrook, Byrne, Kurnik, & McKnight, 1977), with little
change in blood pressure (Gori, Floras, & Parker, 2002; Nyberg &
Westling, 1981). These changes appear to be mediated by concurrent
increases in HR, and a blunting of baroreflex sensitivity facilitates
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increasing sympathetic contributions to cardiovascular control (Gisolf
et al., 2004; Gori et al., 2002).
In this study, the expected brachial artery vasodilatation occurred
during NTG (Anderson et al., 1994; Ignarro et al., 1991). A similar
dilatory effect of ∼24% was observed in the rMCA perfusing the
brain. Unexpectedly, the PLO also caused a small dilatory response,
accounting for ∼4% of the change of CSA. Possible explanations
for the PLO-induced dilatation include a genuine placebo effect, or
random sampling error and/or variability owing to the small sample
size. Another explanation might be that the peppermint oil that forms
a component of theNTG treatmentwas added towater in this study to
produce a similar taste between the PLO andNTG treatments. Sodium
nitroglycerin includes 1% menthol because it potentiates dilatory
effects (Busiashvili, 2003). Peppermint oil containsmenthol, an agonist
for transient receptor potential melastatin 8 (TRPM8; Johnson et al.,
2009). This receptor elicits dilatation in large arteries, such as the
aorta (Johnson et al., 2009). Menthol also attenuates vasoconstriction
in the mesenteric arteries (Sun et al., 2014). We speculate that these
actions might also occur in the cerebral vessels. Regardless, the small
(∼4 ± 19%) dilatation with PLO does not account for the much larger
(∼28 ± 15%) MCA dilatation after NTG, leaving ∼24% attributed to
exogenous NO. Additionally, we subtracted the CSA of PLO fromNTG,
and added that value to the BL values to determine the effect of
exogenous NO. Using Student's two-tailed paired t test, P < 0.05,
indicating that exogenous NO significantly increases CSA.
The observation that exogenous NO causes cerebral artery
dilatation is novel in humans although these data are preceded by
earlier studies in rodents, in which exogenous NTG caused vaso-
dilatation in the large intracranial arteries (Kistler, Vielma, & Davis,
1982). Furthermore, single photon emission computed tomography
measurements of CBF and TCDmeasurements of MCA blood velocity
(to estimate changes in diameter) indicated an increase in calculated
MCA diameter after NTG administration (Dahl, Russell, Nyberg-
Hansen, & Rootwelt, 1989). The present study confirms these earlier
studies, with the first direct measurements of the MCA during
NTG administration in healthy adults. The values of PET,CO2 before
and during NTG were similar in both the MRI and the laboratory,
indicating that the MCA response to NTG occurred independently
of any confounding sources of dilatation elicited by hypercapnia. Of
note, the changes in rMCA CSA observed in the present study (5.2–
6.6 mm2) after NTG are similar to those provided earlier in response
to hypercapnia in different individuals (5.6–6.5 mm2; Coverdale, Gati,
Opalevych, Perrotta, & Shoemaker, 2014).
This study indicates an important role for exogenous delivery of
NO in cerebral conduit vessel control. However, the role of end-
ogenous NO in conduit vessel dilatation remains equivocal. In rats,
pharmacological blockade of NO synthase (NOS) attenuated the
increase in CBF during hypercapnia, demonstrating the role of NO
in cerebrovascular dilatation (Wang, Paulson, & Lassen, 1992). In
contrast, human studies of CBF control using NOS inhibition have
produced conflicting results; some studies reported little effect of
NOS on total CBF during reactive hypercapnic states (Ide, Worthley,
Anderson, & Poulin, 2007), whereas others reported a blunted
increase in MCA blood velocity with hypercapnia after NOS inhibition
(Schmetterer et al., 1997). A major difference between these earlier
studies in humans is that the former measured total flow, whereas
the latter measured blood velocity, not accounting for conduit artery
CSA. Previously, researchers in our laboratory (Coverdale et al., 2014)
and others (Verbree et al., 2014) demonstrated with high-field MRI
that measurement of blood velocity underestimates the changes in
CBF during hypercapnia and hypocapnia. Therefore, the discrepancy
regarding the effect ofNOonCBFcontrol canbe resolvedwith conduit
artery CSA measurements. In this perspective, the combined data
suggest that NO has a specific role in dilating basal cerebral and sub-
cranial arteries.
Measurements of both MCA CSA and flow velocity provide insight
into the effect of NTG on both the conduit artery and the down-
stream vascular bed. Thus, a second major outcome of this study
was the observation that, despite the increase in CSA after NTG and
stable MAP, blood velocity decreased in the MCA such that over-
all CBF remained unchanged. This observation supports previous
findings of reductions in MCA blood velocity after sublingual NTG
administration (Dahl et al., 1989; Zuj et al., 2012). Likewise, others
observed diminished MCA blood velocity but little change in regional
CBF after intravenous infusions of sodium nitroglycerin (Iversen,
Holm, Friberg, & Tfelt-Hansen, 2008; White et al., 2000). The authors
of these previous studies hypothesized that MCA dilatation might
occur, providing a possible explanation for the apparently disparate
observations. The present study provides the data needed to resolve
this uncertainty. By quantifying dilatation in this large conduit vessel,
as well as a reduction in blood velocity after sublingual NTG, we
conclude that exogenous NO affects dilatation in the rMCA but not in
the downstream vascular beds.
The mechanism(s) mediating the lack of downstream dilatation
with NTG remains speculative. The lack of a change in cerebral
and brachial blood flow despite conduit artery dilatation and similar
values of MAP suggests no change in downstream vascular resistance.
Despite known sensitivity of parenchymal vessels to NO (Anderson
et al., 1994; Ignarro et al., 1991; Lavi et al., 2003), the observation
of similar vasomotor responses in the vascular beds of the MCA
and brachial arteries suggests a similar underlying physiology. One
possible mechanism could be a sympathetic nervous system response
that has proportionately greater effects in the downstream versus
conduit vessels, thereby competing with the dilatory effect of the
delivered NO. Previously, it has been reported that NTG leads to
a reflexive increase in plasma noradrenaline to counter the drug-
inducedhypotension (Tassorelli, Blandini, Costa, Preza,&Nappi, 2002).
Other in vivo studies in the rat and guinea-pig determined that
intravenous NTG administration induced increases in noradrenaline,
mimicking biological responses associated with sympathetic neuro-
nal activity in perfused atria and cerebrospinal fluid (Ma & Long,
1991a, b, c; Ma, Schmid, & Long, 1994; Tassorelli et al., 2002). In
humans, chronic NTG administration decreased baroreflex sensitivity
and increased sympathetic neural modulation of heart rate (Gori et al.,
2002). Furthermore, acute reflexive sympathetic vasoconstriction in
the cerebral circulation has been difficult to observe in the human
brain in conditions of stable blood pressure (Sándor, 1999), although
small effects havebeenobservedusing a lower-bodynegativepressure
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suction model (Wilson, Serrador, & Shoemaker, 2003). Thus, although
the literature remains uncertain of the magnitude of sympathetic
activation in the control of CBF (Brassard, Tymko, & Ainslie, 2016),
neurogenic vasoconstriction might be one potential compensatory
mechanism to counter the drug-induced dilatation.
Limitations of this study include the collection of MRI and
laboratory measurements on different days owing to MRI availability.
However, existing data suggest that this effect might be negligible.
For example, TCD estimates of flow velocity are reproducible for up
to 1 week (Demolis, Chalon, & Giudicelli, 1993), and phase-contrast
MRI analyses for estimating CBF are reproducible over 72 days (Spilt
et al., 2002). Furthermore, a single-subject study demonstrated that
over 20 consecutive days, measurement of velocity in the MCA using
TCD is reliable (Vingerhoets& Stroobant, 2002). Additionally, previous
studies in our laboratory demonstrated reproducibility of CBF velocity
measurements on different days (TCD and phase-contrast MRI),
reporting an Intraclass correlation (ICC) of 0.83 (P < 0.001; Coverdale
et al., 2015). Therefore, the data suggest that CBF measurements
are similar on different days. To address this issue further, a multiple
regression of the present results demonstrated that changes in MCA
flow velocity occurred independently of changes in MAP, CO and
PET,CO2 [F(3,6)= 0.382, P= 0.77, R
2 = 0.4].
A second limitation of the present study is that an increase
in baseline PET,CO2 in the MRI versus the laboratory might have
induced different baseline MCA CSA and therefore, responses
to NTG. Additionally, Battisti-Charbonney, Fisher, & Duffin (2011)
demonstrated a sigmoidal relationship of increasing CO2 values and
MCA velocity below a discernable threshold (where above 50 mmHg,
the relationship changes to linear changes in velocity). Between 40
and 50 mmHg, the increase in velocity remains relatively linear. We
do not yet know the CSA–PET,CO2 dose–response relationship, but the
values we obtained occurred on the linear part of the velocity–PET,CO2
curve; therefore, we can infer that the difference between the two
testing sessions may be small. To address this possibility, we evaluated
changes in CSA, although this may not directly address the problem of
baseline CSA affecting the responsiveness of the MCA to exogenous
NO.
A third possible limitation is the time between treatment
administrations and the lack of a second baselinemeasurement before
the second treatment. As mentioned, the half-life of NTG in plasma is
∼2.5 min (Kirsten et al., 1998b). Seven half-lives were allowed after
the NTG treatment to optimize the loss of drug effects. Furthermore,
haemodynamics, velocity levels in the MCA and brachial artery, and
the vessel diameters indicated reinstitution of baseline conditions
between PLO and NTG conditions. Also, the order of treatments
was randomized to ameliorate the potential problem of treatment
carryover effects. Maximal vasodilatation in the brachial artery is
observed 2 min post-NTG administration (Ducharme et al., 1999),
becoming barely detectable after 20 min (Armstrong, Armstrong, &
Marks, 1979). Therefore, physiological measures suggested that a
return to baseline conditions had occurred after 20 min, although
some residual but undetectable NTG effects might have persisted in
some individuals in whomNTGwas given before PLO.
4.1 Conclusion
The rMCA dilated in response to sublingual 0.4 mg NTG, suggesting
an NO-mediated mechanism. This dilatation did not change total
flow because of concurrent reductions in blood velocity, suggesting
differential drug effects on conduit arteries versus microvascular
territories.
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